Information  X 
Enter a valid email address

Okyo Pharma Limited Ord Npv (OKYO)

Date Time Source Announcement
18 May 2022 11:35 am
GNW
OKYO Pharma Limited - PDMR Dealing
  10:10 am
RNS
Director/PDMR Shareholding
17 May 2022 7:00 am
RNS
OKYO Announces Pricing of IPO of ADSs in the U.S.
  7:00 am
GNW
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
16 May 2022 11:12 pm
GNW
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
27 Apr 2022 7:00 am
RNS
Upcoming Presentations at Ophthalmic Conference
  7:00 am
GNW
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
07 Mar 2022 7:00 am
RNS
Additional Listing
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States
23 Feb 2022 7:00 am
RNS
Patent issued: to treat ocular neuropathic pain
  7:00 am
GNW
OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain
21 Feb 2022 5:00 pm
RNS
CLN Conversion, exercise of Warrants, equity issue
  5:00 pm
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity
15 Feb 2022 7:00 am
RNS
Successful Pre-IND Meeting with the FDA on OK-101
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease
01 Feb 2022 7:00 am
RNS
Director/PDMR Shareholding
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings
27 Jan 2022 7:00 am
RNS
Director/PDMR Shareholding
  7:00 am
GNW
OKYO Pharma Limited- PDMR Dealing
26 Jan 2022 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Half-year Report
  7:00 am
GNW
OKYO Pharma Limited - Interim results for the six months to 30 September 2021
14 Dec 2021 7:00 am
RNS
U.S. Patent issued for use of OK-101 to treat DED
  7:00 am
GNW
OKYO Pharma announces issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease
13 Dec 2021 7:00 am
RNS
OK-101:Anti-inflammatory & Pain-Reducing Potential
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease
06 Dec 2021 7:00 am
RNS
IND filing Q3 2022 and Phase 2 initiation Q4 2022
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
01 Dec 2021 7:00 am
RNS
Directorate Change
  7:00 am
GNW
OKYO Pharma Limited: Directorate Change
19 Oct 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
27 Sep 2021 12:17 pm
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
  12:06 pm
RNS
Result of AGM
09 Sep 2021 7:00 am
RNS
Notice of AGM
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting
01 Sep 2021 7:00 am
RNS
Director/PDMR Shareholding
02 Aug 2021 11:57 am
GNW
OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021
  11:32 am
RNS
Annual Financial Report
29 Jun 2021 1:14 pm
GNW
("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications
  7:00 am
RNS
Research Update
17 Jun 2021 3:58 pm
RNS
Directorate Change
12 May 2021 7:00 am
RNS
Holding(s) in Company
07 May 2021 10:07 am
RNS
Additional Listing
05 May 2021 11:53 am
RNS
Publication of a Prospectus
28 Apr 2021 7:00 am
RNS
Positive Data in an Animal Model using OK-201
  7:00 am
GNW
("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
29 Mar 2021 7:00 am
RNS
Appointment of Chief Scientific Officer
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
03 Mar 2021 7:00 am
RNS
Issue of Equity
01 Mar 2021 7:00 am
RNS
Issue of Equity
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
23 Feb 2021 7:00 am
RNS
Patent for treating Ocular Pain and Inflammation
  7:00 am
GNW
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
19 Jan 2021 7:00 am
RNS
Filing patent application for the use of Chemerin
  7:00 am
GNW
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
14 Jan 2021 4:41 pm
RNS
Second Price Monitoring Extn

a d v e r t i s e m e n t